A NSCLC patient with EGFR 19del received gefitinib followed by osimertinib because of the emergence of EGFR T790M, then EGFR C797S and LMNA-NTRK1 fusion were detected when resisting to osimertinib. Here, NTRK1 is linked to non-small cell lung carcinoma.